Novel Drug Discovery for the Treatment of Cancer
Welcome to Sentinel Oncology. Our aim is to discover new chemical entities for the use in better treatments for cancer.
Learn about our research and development
Become a Product Partner
Sentinel Oncology is seeking partners to out-license products from its oncology pipeline at the pre-clinical development phase.
The Sentinel pipeline contains a number of novel small molecule programmes designed to inhibit key targets important in cancer therapy including angiogenesis & invasion, DNA repair pathways and tumour hypoxia.
The CHK1 programme is currently undergoing pre-clinical evaluation following successful in-vivo proof of concept studies.
News
October 2008
Biopartnering Europe
Sentinel Oncology will be attending Biopartnering Europe at the QEII conference centre in London on 13-14th October. Why… read more
January 2008
Sentinel Oncology announce pre-clinical programme available for partnering
Sentinel Oncology announce that their Checkpoint kinase 1 programme is available for pre-clinical partnering. To arrange… read more
October 2007
Seeding Drug Discovery initiative grant £1.3m
Sentinel Oncology Ltd secures £1.3M investment from Wellcome Trust to develop innovative cancer drugs. Funds will… read more